Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

31.03.2021 | short review | Ausgabe 2/2021 Open Access

memo - Magazine of European Medical Oncology 2/2021

DNA methylation as predictive marker of response to immunotherapy?

memo - Magazine of European Medical Oncology > Ausgabe 2/2021
PhD, MSc. Gerwin Heller
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Immunotherapy is one of the major breakthroughs in cancer treatment. However, many patients do not benefit from this type of therapy. Thus, there is an urgent need for a strategy to predict treatment efficacy before start of therapy. The role of certain genetic and epigenetic factors as potential predictive markers for response to immunotherapy is discussed in this short review.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2021

memo - Magazine of European Medical Oncology 2/2021 Zur Ausgabe